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Abstract
 
Signal transducer and activator of transcription (STAT) proteins are latent transcription factors
that mediate a wide range of actions induced by cytokines, interferons, and growth factors. We
now report the development of thymic T cell lymphoblastic lymphomas in transgenic mice in
which Stat5a or Stat5b is overexpressed within the lymphoid compartment. The rate of lym-
phoma induction was markedly enhanced by immunization or by the introduction of TCR
transgenes. Remarkably, the Stat5 transgene potently induced development of CD8
 
 
 
 T cells,
even in mice expressing a class II–restricted TCR transgene, with resulting CD8
 
 
 
 T cell
lymphomas. These data demonstrate the oncogenic potential of dysregulated expression of a
STAT protein that is not constitutively activated, and that TCR stimulation can contribute
to this process.
Key words: Stat5 • TCR • lymphoma • DNA microarray • CD8
 
 
 
 T cell
 
Introduction
 
The Janus family tyrosine kinase (JAK)–signal transducer
and activator of transcription (STAT)
 
*
 
 pathway is a major
signaling pathway used by cytokines and interferons (1–3).
STAT proteins have also been linked to oncogenesis (4).
Constitutive activation of STATs, as evidenced by consti-
tutive tyrosine phosphorylation and DNA binding activity,
has been found associated with cellular transformation
(5–8) and in various human tumors (4, 9, 10), and corre-
spondingly, a constitutively activated form of Stat3 is onco-
genic (11). Recently, retroviral insertional mutagenesis (RIS)
in the Stat5a gene was found in a murine pre-B cell lym-
phoma that also exhibits constitutive STAT activation (12),
and we have found RISs associated with Stat5b as well as
Stat5a in two cases of murine AKXD Burkitt-like B cell
lymphoma (online supplemental Fig. S1). Interestingly, in
one form of acute promyelocytic leukemia, Stat5b is part of
a retinoic acid receptor (RAR) fusion oncoprotein, but this
lacks the Stat5b SH2 domain and acts based on its ability to
repress normal RAR function and enhance IL-6–mediated
activation of Stat3 (13, 14).
We now report the development of T cell lymphoblastic
lymphomas in transgenic mice expressing nonactivated
(HA-tagged WT) forms of either Stat5a or Stat5b and
thereby provide direct evidence for the role of Stat5 in on-
cogenesis. Moreover, we demonstrate in these mice that a
marked synergistic effect in the rate of tumor development
is conferred by antigen-activation or by coexpression of ei-
ther MHC class I– or class II–restricted TCR transgenes.
 
Materials and Methods
 
Generation of Mice.
 
Stat5a and Stat5b transgenic mice were gen-
 
erated and bred onto Stat5a
 
 
 
/
 
 
 
, Stat5b
 
 
 
/
 
 
 
, or Stat5a
 
 
 
/
 
 
 
Stat5b
 
 
 
/
 
 
 
double knockout backgrounds as part of a series of experiments
to evaluate functional similarities and differences between Stat5a
and Stat5b (15), as well as onto WT C57BL/6 and BALBc back-
 
The online version of this article contains supplemental material.
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*
 
Abbreviations used in this paper:
 
 EMSA, electrophoretic mobility shift
assay; STAT, signal transducer and activator of transcription.T
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grounds. Stat5 transgenic mice were also mated with mice ex-
pressing a TCR transgene specific for a peptide of pigeon cyto-
chrome c (amino acids 81–104) presented by the MHC class II
molecule I-Ea/k (TCR-Cyt-5C.C7-I/RAG2
 
 
 
/
 
 
 
 mice; Taconic).
We analyzed CD4/CD8 and CD44/IL-2R
 
 
 
 (CD25) profiles
(gated on CD4
 
 
 
/CD8
 
  
 
[DN]) of mice that were heterozygous for
the Stat5b and 5C.C7 TCR transgenes and RAG2 on the H-2
 
k/d
 
or H-2
 
k/b
 
 MHC backgrounds. Similarly, Stat5b transgenic mice
were mated with HY TCR transgenic to generate mice that were
heterozygous for the Stat5b and HY TCR transgenes and RAG2
on the H-2
 
b/b
 
 MHC background. Stat5b transgenic, 5C.C7 TCR
transgenic, and 5C.C7 TCR/Stat5b transgenic mice were immu-
nized intraperitoneally with 100 
 
 
 
g of cytochrome c (Sigma-
Aldrich) mixed with 100 
 
 
 
l CFA (Pierce Chemical Co.).
Mice lacking expression of both the common cytokine recep-
tor 
 
 
 
 chain (
 
 
 
c
 
) and RAG2 (Taconic) were injected subcutane-
ously with a mixture of 10
 
6
 
 fresh thymic and cervical lymph node
tumor cells. Tissues (thymus, spleen, and lymph nodes) were
fixed by immersion in 10% formalin and embedded in paraffin by
standard procedures. Sections were stained with hematoxylin and
eosin. All experiments were performed under protocols approved
by the NIH Animal Use and Care Committee and followed the
NIH guidelines “Using Animals in Intramural Research.”
 
Flow Cytometric Analysis.
 
Single-cell suspensions from thy-
mus, spleen, and lymph node were stained and analyzed using a
FACSort
 
®
 
 with CELLQuest™ software (Becton Dickinson).
Anti-CD4-FITC, -PE, and -Cy-Chrome; anti-CD8-PE and
-APC; anti-IL-2R
 
 
 
 (CD25)-FITC and-PE; anti-CD44-Cy-
Chrome; anti-IL-2R
 
 
 
-FITC and-PE; anti-pan-NK cells (DX5)-
FITC; anti-V
 
 
 
2–6, 8, 10, 11-FITC and-PE; V
 
 
 
11-FITC; and
anti-CD3-APC were from BD Biosciences.
 
Western Blotting.
 
Whole cell extracts (5–20 
 
 
 
g/sample) were
fractioned on 8% SDS polyacrylamide gels (Invitrogen/
NOVEX™) and transferred to Immobilon-P membranes (Milli-
pore). After blocking with 5% milk, the blots were incubated
with rabbit anti-phospho-Stat5 (Tyr694), anti-phospho-Stat3
(Tyr705; Cell Signaling Technology) or mouse anti-HA (Santa
Cruz Biotechnology, Inc.), washed, and incubated with a horse-
radish peroxidase-conjugated anti–rabbit or anti–mouse antibody
(Nycomed Amersham). Blots were developed with an enhanced
chemiluminescent substrate (Pierce Chemical Co.).
 
Electrophoretic Mobility Shift Assays.
 
Electrophoretic mobility
shift assays (EMSAs) were performed using nuclear extracts and a
 
 
 
-casein probe as described previously (16). For supershifting as-
says, nuclear extracts were preincubated for 20 min with antibod-
ies to Stat3 or Stat5b (Zymed Laboratories).
 
RNA Purification and Affymetrix Gene Chip Analysis.
 
RNA
was isolated using a kit (RNeasy
 
®
 
; QIAGEN) and processed to
cRNA probes for GeneChip
 
®
 
 analysis according to the manufac-
turer’s instructions (Affymetrix, Inc.). The probes were hybridized
to U75A GeneChip
 
®
 
 (Affymetrix, Inc., with oligonucleotides
corresponding to 12,489 transcripts per microarray), washed, and
scanned (Hewlett Packard Gene Array scanner G2500A) accord-
ing to procedures outlined by the manufacturer (Affymetrix, Inc.).
Data were analyzed using “unsupervised” hierarchical cluster-
ing (17, 18). This approach “seeks structure inherent in the data
and assumes no a priori classification of genes or samples, with the
goal of identifying related expression pathways of genes or sam-
ples”(17). Results corresponding to 4372 genes whose expression
was detected (‘present’; see online supplemental material) in all
groups (WT spleen [WT
 
S
 
], Stat5b transgenic spleen [TG
 
S
 
], WT
CD8 splenocytes [CD8WT
 
S
 
], Stat5b transgenic CD8 T spleno-
cytes [CD8TG
 
S
 
], WT thymus [WT
 
T
 
], Stat5b transgenic thymus
 
[TG
 
T
 
], lymphoma spleen [ONCO
 
S
 
], and lymphoma thymus
[ONCO
 
T
 
]) were expressed as a dendogram (samples with the
most similar expression profiles are directly connected and those
less similar are connected through additional “branches” of the
dendogram “tree”). Further analysis was done using 7195 genes
whose expression was detected (‘present’) in splenic and/or thy-
mic groups. We identified 1512 genes that were more highly ex-
pressed in ONCO
 
S
 
 or ONCO
 
T
 
 than in at least one of the other
groups listed above for further examination. The raw data and a
complete list of the genes will be available at www.nhlbi.nih.gov/
labs/supplements.
To examine gene expression patterns over time, 5C.C7 TCR
transgenic mice, with and without the Stat5b transgene, were
killed at 2, 3, 6, 12 or 13 wk of age. CD8
 
 
 
 thymocytes were en-
riched using CD4 paramagnetic beads and an autoMACS (Mil-
tenyi Biotec). RNA was extracted and hybridized to U75A
GeneChips
 
®
 
, as described above, and data were analyzed using
hierarchical clustering (18). Analysis was performed using unsu-
pervised hierarchical clustering (as above) for 6250 genes whose
expression was detected (“present”; see online supplemental ma-
terial) in any of four groups (5C.C7 single transgenic [group 1],
Stat5b/5C.C7 double transgenic 2–3 wk old [group 2], Stat5b/
5C.C7 double transgenic 6–8 weeks old [group 3], Stat5b/5C.C7
double transgenic 12–13 wk old [group 4]) were presented as a
dendogram. In addition, genes that were found to be increased in
lymphomas in Stat5b transgenic mice (see Fig. 4 C) were exam-
ined over time in 5C.C7 and Stat5b/5C.C7 mice.
 
Isolation and Stimulation of Enriched CD4
 
 
 
/CD8
 
 
 
 DP Thy-
mocytes.
 
CD4
 
 
 
/CD8
 
 
 
 (DP) thymocytes were enriched using
CD8
 
 
 
 paramagnetic beads and an autoMACS (Miltenyi Biotec),
and 4 
 
 
 
 10
 
7
 
 cells were cultured in 10 ml for 16 h with phorbol-
12-myristate-13-acetate (PMA, 0.2 ng/ml) 
 
 
 
 ionomycin (0.2
 
 
 
g/ml; Calbiochem). Cells were then washed and cultured in
RPMI 1640 medium containing 10% FBS and 2 mM 
 
l
 
-glu-
tamine, and antibiotics (complete medium) for 48 h (day 3 cells;
reference 19).
 
Proliferation Assays.
 
Fresh thymocytes were cultured for 48 h
in complete medium, with or without 1 nM IL-7, in 96 well flat-
bottom plates (2 
 
 
 
 10
 
5
 
 cells/well) with and without soluble anti-
CD3 (2 
 
 
 
g/ml) plus anti-CD28 (2 
 
 
 
g/ml). Wells were pulsed with
1 
 
 
 
Ci of [
 
3
 
H]thymidine (6.7 Ci/mmol; NEN Life Science Prod-
ucts) for the last 9 h of culture. Thymocytes from heterozygous
TCR-Cyt-5C.C7-I/RAG2
 
 
 
/
 
 
 
 cytochrome c TCR transgenic ex-
pressing the Stat5b transgene, with and without lymphoma, were
incubated with cytochrome c (200 
 
 
 
g/ml; Sigma-Aldrich) for 72 h.
Wells were pulsed with 1 
 
 
 
Ci of [
 
3
 
H]thymidine (6.7 Ci/mmol;
NEN Life Science Products) for the last 9 h of culture.
 
Online Supplemental Material.
 
Supplemental Fig. S1 shows
RISs in the Stat5a/Stat5b genomic locus in two mice with
AKXD Burkitt-like lymphoma. This suggests the oncogenic po-
tential of RISs in either the Stat5a or Stat5b loci. Supplemental
Table S1 shows a complete listing of genes from the microarray
analyses presented in Fig. 4, B and C.  Supplemental Table S2
shows a complete listing of genes from the microarray analyses
presented in Fig. 7 E. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20021548/DC1. 
 
Results
 
Mice Overexpressing Stat5 Develop CD8
 
 
 
 Lymphoblastic
Lymphoma.
 
Stat5a and Stat5b are highly-related proteins
that are required for normal lactation, growth, hemato-T
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poiesis, and immune function (20–26). We generated
Stat5a and Stat5b transgenic mice, using a vector contain-
ing the H-2K
 
b
 
 promoter and IgM enhancer, in order to
evaluate distinctive versus overlapping actions of these
highly homologous proteins (
 
 
 
90% identical; reference 27)
within the lymphoid system. Two Stat5b founder lines
(TG1, TG2) and one Stat5a line that expressed the appro-
priate transgene in the immune system were evaluated (Fig.
1; reference 15). Both Stat5a and Stat5b transgenic mice
have increased splenic CD8
 
 
 
 T cells at the earliest point
examined (12 d; reference 15). Unexpectedly, as the mice
aged, many developed striking lymphadenopathy that we
noted at a median age of 205 d (range 78–456 d, Table I
and Fig. 2, A and B), with enlarged thymuses (unpublished
Figure 1. Anti-HA Western blotting of splenic and thymic lysates from
two Stat5b transgenic lines (TG1 and TG2) and one Stat5a line (TGA).
WT lysates are included as controls.
 
Table I.
 
Lymphomas in Stat5 Transgenic Mice
 
Mouse
ID
 
b
 
Age
days
 
c
 
Tumor phenotype
 
d
 
Transgene Genetic background
 
a
 
CD4
 
 
 
CD8
 
 
 
CD4
 
 
 
CD8
 
 
 
TCR V
 
 
 
d
 
Stat5b TG1
 
e
 
Stat5a
 
 
 
/
 
 
 
 Stat5b
 
 
 
/
 
 
 
Onco 1 92 ND ND ND
(C57BL/6 
 
 
 
 129) Onco 2 155 (E)
 
  
 
V
 
 
 
10
Onco 3 241 (E)
 
  
 
V
 
 
 
4
Onco 4 270 (E)
 
  
 
V
 
 
 
3
Onco 5 353 ND ND ND
Onco 6 370 (E)
 
  
 
V
 
 
 
6
Stat5a
 
 
 
/
 
 
 
 (C57BL/6 
 
 
 
 129) Onco 7 78 ND ND ND
Onco 8 337 ND ND ND
Stat5a
 
 /  Stat5b / 
(C57BL/6   129)
Onco 9 133 (E)    ND
WT (C57BL/6) Onco 10 113 (E)    V 10
Onco 11 162 (E)    ND
Onco 12 196 (E)    V 2
Onco 13 380 (E)    V 2
Onco 14 456 ND ND ND
Stat5b TG2e Stat5a /  (C57BL/6) Onco 15 253 (E)    ND
Stat5a TGe Stat5a /  (C57BL/6) Onco 16 116 ND ND ND
Onco 17 234 ND ND ND
Onco 18 289 ND ND ND
Stat5b / 
(C57BL/6   129)
Onco 19 207 (E)    ND
WT (C57BL/6) Onco 20 162 (E)    V 3
Characteristics of the first 20 Stat5a and Stat5b transgenic mice that developed lymphoblastic lymphoma, including genetic background, age, and cell surface
phenotypes.
aBackground is either C57BL/6, or mixed C57BL/6   129; with varied Stat5 knockout backgrounds as indicated.
bID   arbitrary mouse number, mice are referred to as Onco (oncogenesis), and grouped for convenience. 
cE   euthanasia at stated age; other mice were found dead at the stated age.
dDetermined by cell surface staining.
eRate of tumor formation is 25% for TG1, 5% for TG2, and 8% for the Stat5a TG.T
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data), and spleens (Fig. 2 C). Normal lymph node architec-
ture was disrupted by neoplastic lymphocytes (Fig. 2 D)
with cytologic features consistent with the diagnosis of T
cell lymphoblastic lymphoma (Fig. 2 E). The first 20 lym-
phomas occurred in 15 Stat5b transgenic mice (14 from the
TG1 and one from the TG2 transgenic lines), and five
Stat5a transgenics (Table I). The Stat5b transgenic line with
the highest expression within the thymus (TG1) had the
highest rate of tumor formation (25% of 60 mice over 4 mo
old), the Stat5a transgenic line had intermediate rate of tu-
mor formation (8% of 65 mice over 4 mo old), while
Stat5b TG2 line had only 1 lymphoma out of 20 mice over
4 mo old, correlating thymic Stat5 transgenic expression
(Fig. 1, lanes 3, 5, and 9) and lymphoma formation. Ini-
tially, mice were bred onto Stat5a / , Stat5b / , or
Stat5a / /Stat5b /  backgrounds as part of a study to
compare the actions of Stat5a and Stat5b, but lymphomas
have also developed on a WT background (Table I).
Of the 12 lymphomas from Table I analyzed by flow cy-
tometry, 10 had populations of both CD4 CD8  double
positive and CD8  single positive cells (Table I, Onco 2,
4, 9–13, 15, 19, and 20; Fig. 3 A, Onco 12, panels a, b, and
c) and two had predominantly CD8  cells (Table I, Onco
3 and 6; Fig. 3 A, Onco 3, panels e, f, and g) in thymus,
spleen, and lymph nodes. Of eight mice examined for
TCR-  usage, one exhibited two prominent populations
and seven a single prominent population based on V 
staining (e.g., Onco 12 cells stained only for V 2 (Table I
and Fig. 3 B, panels a versus b), while Onco 3 had only
V 4  staining (Table I, and Fig. 3 B, panels c versus d).
We confirmed the monoclonal nature of the tumor in two
lymphomas by PCR analysis of TCR   rearrangements
(reference 28; unpublished data). Subcutaneous injection
of malignant cells into  c/RAG2 double KO mice resulted
in tumor formation at the site of injection; cells from these
tumor masses had flow cytometric profiles indistinguish-
able from the original transplanted donor cells (Fig. 3 A,
panels d versus a, b, c and h versus e, f, g; and Fig. 3 B,
panels g versus a, and h versus d). Thus, both Stat5a and
Stat5b transgenes predisposed to development of T cell
lymphoblastic lymphoma.
Neither Stat5 Nor Stat3 Is Constitutively Active in the Lym-
phoma Tissues. Oncogenesis has been correlated previ-
ously with the constitutive expression of activated STAT
proteins (4, 11, 29). Surprisingly, however, we detected lit-
tle if any constitutively-activated Stat5 or Stat3 in lym-
phoma tissues by anti-phospho-Stat5 Western blotting
(Fig. 3 C, lanes 4–7), by anti-phospho-Stat3 (Fig. 3 D,
lanes 2–5), or by electrophoretic mobility shift assays
(EMSAs; Fig. 3 E, lanes 4, 7, 12, 14, and 17). This is con-
sistent with our transgene being a WT (i.e., not constitu-
tively activated) form of Stat5. However, stimulation of
lymphocytes in vitro with IL-2 or IL-7, two cytokines that
can activate Stat5, potently augmented DNA binding ac-
tivity in Stat5b tumor lysates to levels higher than seen in
lysates from WT mice (Fig. 3 E, lanes 5, 6, 13, and 18 ver-
sus 2, 3, 9, 16, and 22). As expected, Stat5b was a major
protein in the binding complex based on supershifting with
anti-Stat5b (lane 20), whereas anti-Stat3 had no effect (lane
19). Immunoprecipitation with anti-HA, followed by anti-
phospho-Stat5 Western blotting, confirmed phosphoryla-
tion of the transgene in lymphoid tissues from Stat5b trans-
genic mice with and without lymphoma (reference 15, and
unpublished data).
DNA Microarray Indicates the Lymphomatous Cells Have
Characteristics of Immature Thymocytes. To investigate if the
transgene augmented or repressed expression of certain
genes, we next performed microarray analysis of mRNAs
isolated from WT and Stat5b transgenic mice. Despite the
effects of Stat5 on peripheral CD8  T cell homeostasis
(15), there was little difference between the splenic gene
expression patterns of WT and Stat5b transgenic mice (Fig.
4 A, “splenic cluster”). In contrast, the expression pattern
seen in Stat5b transgenic lymphomatous spleens was more
similar to that of WT thymuses (Fig. 4 A, “thymic clus-
ter”). The augmented expression in the tumors of genes
such as TCR , RAG1, RAG2, and TdT (terminal deoxy-
transferase) that are involved in T cell development (Fig. 4
B) is consistent with the diagnosis of precursor T cell lym-
phoblastic lymphoma (30). Microarray analysis also identi-
fied a group of genes whose increased expression appeared
Figure 2. Lymphoblastic lymphoma in a representative Stat5b trans-
genic mouse. Prominent cervical adenopathy (A and B) and splenomegaly
(C) were evident. (D and E) A representative cervical lymph node with
round nuclei with stippled chromatin, prominent nucleoli, and frequent
mitotic figures.T
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to be distinctive for the lymphoma tissue regardless of tissue
source (Fig. 4 C).
Stat5b Transgenic Thymocytes Exhibit Enhanced Activation
and Proliferation. Because of the thymic origin of the
lymphoma, we further evaluated thymocytes from WT
and Stat5b transgenic mice in which lymphomas had not
yet developed. After stimulation with PMA plus ionomy-
cin (PI; Fig. 5 A), or anti-TCR  plus anti-CD2 (unpub-
lished data), both WT and Stat5b transgenic thymocytes
had an increase in the percentage of CD8  single positive
T cells by day 1 (Fig. 5 A, panel c versus a and d versus b),
and this increase was preferentially sustained in Stat5b
transgenic mice until at least day 3 (Fig. 5 A, panel f ver-
sus e). The percentage of CD4  cells was also increased in
response to PI, but little if any difference was seen be-
tween WT and Stat5b transgenic mice (Fig. 5 A, panels d
versus c and f versus e). The thymocyte differentiation/
activation markers CD44 and IL-2R  (CD25; reference
31) were more highly expressed on thymocytes from
Stat5b transgenic mice as compared with WT mice (Fig. 5
B, panels d versus c and f versus e), and these Stat5b trans-
genic thymocytes proliferated more vigorously than wild
type thymocytes in response to anti-CD3 plus anti-CD28,
IL-7, or a combination of these stimuli (Fig. 5 C), or to
stimulation with anti-TCR  plus anti-CD2 (unpublished
data). Thus, after various exogenous stimuli, Stat5b thy-
moctes, as compared with WT thymocytes, proliferated
more vigorously and exhibited an increase in the number
Figure 3. Analysis of lymphoblastic lymphoma cells
from Stat5 transgenic mice. (A) Augmented CD4 /CD8 
and/or CD8  T cells in Stat5b transgenic mice. Flow cy-
tometric analysis of cells from thymus (panels a, e, and i),
spleen (panels b, f, and j), and cervical lymph node (panels
c and g). Also shown is the CD4/CD8 profile of subcuta-
neous cervical lesions in a RAG/ c double KO mouse 3
wk after subcutaneous injection of fresh tumor cells (panels
d and h). (B) V 2-FITC and V 4-PE staining in two rep-
resentative tumors demonstrating a single population of
positively staining cells. Although Onco 12 had a substan-
tial V 2-negative population, staining for V 3–6, 8, 10,
11, and V 11 was negative. Tumor masses resulting from
the injection of lymphoma cells into RAG/ c double KO
mice maintained the same expression profile as the donor
cells (panels g vs. a and h vs. d). (C) No constitutive phos-
phorylation of Stat5a or Stat5b, as evaluated by anti-phos-
pho-Stat5 Western blotting, is seen in the tumor lysates
(lanes 4–7), whereas the positive control (Stat5b transgenic
splenocytes stimulated with IL-2 for 30 min) confirmed
the function of the anti-phosphoStat5 antibody (lane 11).
(D) No constitutive phosphorylation of Stat3 was detected
by anti-phospho-Stat3 Western blotting in tumor lysates
(lanes 2–5), whereas the positive control (tumor lysates
stimulated with IL-6 for 30 min) confirmed the function of
the anti-phospho-Stat3 antibody (lane 7). (E) EMSAs using
a   -casein probe and the indicated samples. Cells from
WT (lanes 1–3, 8, 9, 15, 16, 21, 22), transgenic (TG; lanes
10, 11), or mice with tumors (Onco; lanes 4–7, 12–14, 17–
20) were not stimulated or stimulated with IL-2 or IL-7, and
DNA binding activity measured. Supershifting with anti-
Stat5 or Stat5b is shown in lanes 19 and 20, respectively.T
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84 Oncogenic Potential of Stat5
of CD8  T cells and the percentage of these cells that
were activated.
Antigen Stimulation Increases Rate of Lymphoma Forma-
tion. Because of the effect of anti-CD3 stimulation on the
proliferation and activation of Stat5b transgenic thy-
mocytes, we hypothesized that TCR activation might pro-
mote the growth and/or malignant transformation in
Stat5b transgenic mice, consistent with a suggested role for
immune receptor stimulation in certain lymphoid neo-
plasms (32, 33). In this regard, coexpression of a TCR
transgene greatly augmented thymic CD8  T cell develop-
ment in the Stat5b transgenic mice. Remarkably, this oc-
curred not only with the class I–restricted HY TCR
trangene (unpublished data), but also with the 5C.C7 class
II–restricted TCR trangene (Fig. 6 A, panels b versus a),
even though class II restricted TCRs normally direct devel-
opment in the CD4 pathway. Interestingly, expression of
the 5C.C7 TCR transgene increased the percentage of
DN1 cells (CD4 /CD8  double negative cells that are
CD44hiIL-2R  ; panel d versus c). After immunization,
Stat5b/5C.C7 TCR transgenic mice had more CD8  T
cells than mice that expressed only the 5C.C7 TCR trans-
gene (Fig. 6 B, panel b versus a), and there was an increase
in the percentage of these CD8  T cells that were activated
(CD44hiIL-2R  ; Fig. 6 B, panel e versus d). The CD8 
T cells were V 11 /V 3  (Fig. 6 B, panels g and h), con-
firming that their selection was via the cytochrome c-spe-
cific 5C.C7 TCR (34).
Strikingly, Stat5b transgenic mice coexpressing a TCR
transgene developed lymphoma at a much younger age (57
and 70 d, respectively, for HY and 5C.C7 transgenic mice)
than Stat5b transgenic mice on a non-TCR transgenic
background (median of 205 d; Fig. 6 C, and unpublished
data). Stat5b/5C.C7 trangenic mice, whether immunized
with cytochrome c in CFA (Fig. 6 B, panel c and f), or not
immunized, developed lymphomas that were V 11 /
V 3  (Fig. 6 B, panel i) and vigorously proliferated to IL-7
(Fig. 6 D). Because of the effect of the TCR transgenes, we
immunized 6–8-wk-old Stat5b transgenic mice lacking the
TCR transgene with ovalbumin/CFA. Remarkably, tu-
mors were evident by 3 mo of age (median 72 d; Fig. 6 C),
whereas this was not observed in WT controls. Immuniza-
tion of Stat5b/5C.C7 double trangenic mice did not alter
the age at which these mice developed lymphoma (Fig.
6 C). Thus, malignant transformation in Stat5b transgenic
mice was increased by antigenic/adjuvant stimuli. Most of
the thymic tumors arising in younger mice were detected
before obvious splenic involvement, as evaluated by CD4/
CD8 and V /V  profiles.
Analysis of Stat5b/5C.C7 Double Transgenic Mice Over
Time. To investigate the mechanism underlying the on-
cogenic transformation, we analyzed Stat5b/5C.C7 double
transgenic mice over time. As noted above, these mice de-
velop lymphoblastic lymphoma at a median age of 70 d,
and all double transgenic mice over 3 mo of age we have
studied had lymphoma.
Unlike their 5C.C7 littermates, Stat5b/5C.C7 double
transgenic mice exhibit an expansion of CD8  T cells over
time (Fig. 7, A and B). This expansion of CD8  T cells was
evident at two weeks of age (Fig. 7 B, panel g versus a) and
was marked in the older double transgenic mice (Fig. 7 B,
panels i and j). 5C.C7 mice without the Stat5b transgene
exhibited either of two phenotypes: an age-dependent de-
letion of thymocytes (Fig. 7 B, panels c and d, note the low
cellularity) or an expansion of CD4  cells (Fig. 7 B, panels
e and f).
Proliferation of thymocytes to anti-CD3 stimulation was
greater in the Stat5b/5C.C7 mice than in 5C.C7 litter-
mates (Fig. 7 C). This was evident in mice as young as 2
wk old and increased over time until 8 wk of age. The
older double transgenic mice (12–13 wk old) had enlarged
thymuses consistent with lymphoblastic lymphoma, and
some of these mice had more vigorous thymocyte prolifer-
ation in response to anti-CD3 stimulation, while others
had a more vigorous response to IL-7 (Fig. 7 C, and un-
published data).
Figure 4. Oligonucleotide (GeneChip®) microarray analysis indicating
that the lymphomas are of thymic origin. (A) Shown is a dendogram cor-
responding to 4372 genes whose expression was detected in all groups
(WTS, TGS, CD8WTS, CD8TGS, WTT, TGT, ONCOS, ONCOT). The
“Thymic” and “Splenic” clusters refer to samples whose expression pat-
terns were most similar to those found in normal thymus and spleen, re-
spectively (i.e., they “coclustered”). Note that the pattern observed for
CD8  T cell enriched splenocytes was similar to that observed in total
splenocytes. The mice with lymphomas are designated as in Table I. (B)
A selection of genes that were similarly expressed in the lymphomas and
thymic tissue. (C) Genes that were more highly expressed ( 1.4-fold in-
creased) in lymphomas than in any of the WT or TG tissue samples.
Green squares correspond to genes with relatively low level of expression
and red squares to genes with relatively high level of expression (e.g., in
one of the TGT samples [second from the right] fewer genes were highly
expressed). The raw data and a complete list of the genes will be available
at www.nhlbi.nih.gov/labs/supplements.T
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We next evaluated gene expression in CD8  thymocytes
over time using microarrays. Unsupervised hierarchical
clustering revealed that the expression profiles of CD8  T
cells from 5C.C7 single transgenic mice, regardless of age,
were similar and formed a distinct cluster (Fig. 7 D). Con-
versely, the expression profiles of CD8  T cells from the
Stat5b/5C.C7 double transgenic correlated with age in that
the expression profiles of ‘premalignant’ CD8  cells of mice
between 2 and 8 wk were similar, whereas the profiles of
mice 12–13 wk of age with overt tumors formed a separate
group in the clustering analysis. In this longitudinal study
we also examined the expression over time of those 35
genes that were shown in Fig. 4 C to be more highly ex-
pressed in mice with lymphoblastic lymphoma in the WT
background. We found that 18 of these 35 genes were
more highly expressed in Stat5b/5C.C7 double transgenics
than in 5C.C7 single transgenic mice. These 18 genes ap-
peared to fall into two major groups; the expression of 12
genes (Fig. 7 E, group a) was not increased until 12–13 wk
of age, a time when the mice exhibited overt evidence of
lymphoblastic lymphoma, whereas the other 6 genes (Fig. 7
E, group b) were more highly expressed in Stat5b/5C.C7
double transgenic CD8  thymocytes from an early age.
One gene that was increased in young Stat5b/5C.C7 dou-
ble transgenic thymocytes, as well as in the lymphoblastic
lymphoma in Stat5b/WT mice, is the gene encoding pro-
tein tyrosine phosphatase non receptor type 13 (Ptpn13).
Interestingly, this gene was not increased in Stat5b trans-
Figure 5. Effect of the Stat5b and TCR
transgenes on CD4/CD8 flow cytometric pro-
files, activation state, and proliferative potential
of thymocytes. (A) CD4/CD8 profiles for wild
type vs. Stat5b transgenic thymocytes. CD4 /
CD8  (DP) thymocytes (day 0) were cultured
with PMA   ionomycin for 24 h (day 1) fol-
lowed by 48 h in RPMI (day 3 cells; reference
19). Similar results were obtained if anti-TCR 
(H57–597)   anti-CD2 (RM2–5) was used in-
stead of PMA   ionomycin. (B) CD44/IL-2R 
profiles (gated on total population) for the
same cells as in A. (C) Stat5b transgenic thy-
mocytes exhibit augmented proliferation to
IL-7, to anti-CD3   anti-CD28, or to both
stimuli.T
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genic mice on a WT background until the development of
lymphoma. Ptpn13 (35) is also known as Fas-associated
phosphatase-1 (FAP-1; reference 36) and is a negative regu-
lator of FAS-mediated apoptosis in human cancer cells (37).
Discussion
We previously found that overexpression of Stat5 pro-
teins can increase peripheral CD8  T cell numbers by aug-
menting proliferation and cell survival (15), but we did not
anticipate that such overexpression would predispose to
malignant transformation. The dysregulated expression of
the transgenic Stat5 proteins could theoretically result in a
state of hyperresponsiveness to cytokines, and in fact the
level of Stat5 DNA binding activity in response to IL-2 or
IL-7 was higher than seen in WT mice. However, Stat5
was not constitutively activated, and our DNA microarray
gene expression studies revealed relatively few differences
Figure 6. Stat5 transgenic mice are more
prone to malignant transformation in the pres-
ence of a TCR transgene. (A) Mice that were
heterozygous for the Stat5b and 5CC7 TCR
transgenes (b and d) exhibited an increase in ac-
tivated CD8  T cells as compared with mice
only carrying the 5CC7 transgene (a and c).
CD4/CD8 (a and b), CD44/IL-2R  (gated on
CD4 /CD8  [DN], c and d), and V 3/V 11
(e and f) profiles of mice that were heterozy-
gous for the 5C.C7 TCR transgene and RAG2
(panels a, c, and e) and also for the Stat5b trans-
gene (panels b, d, and f) are shown. (B) 5C.C7
TCR transgenic mice (panels a and d) and
5C.C7 TCR/Stat5b transgenic mice (panels b,
c, e, and f) were immunized intraperitoneally
with cytochrome c/CFA, and CD4/CD8 (pan-
els a, b, and c) and CD44/IL-2R  (gated on
CD8 , panels d, e, and f) profiles were analyzed
upon sacrifice 3 wk later. The mouse repre-
sented by panels b, e, and h had no evidence of
lymphoma whereas the mouse represented by
panels c, f, and i had an enlarged thymus consis-
tent with lymphoblastic lymphoma. In A and B,
total thymocyte numbers are shown in paren-
theses on the far right. (C) Age of diagnosis of
lymphomas. Shown are Stat5b transgenic mice,
not immunized or immunized with ovalbumin/
CFA, and Stat5b/5C.C7 double transgenic
mice that were either not immunized or immu-
nized with cytochrome c/CFA. Each point
represents a single mouse, and the median for
each group is indicated by the horizontal bar.
(D) Proliferation of thymocytes from mice that
were heterozygous for both the Stat5b and
5CC7 TCR transgenes, with and without lym-
phoma, after incubation with cytochrome c
(200  g/ml) or 1 nM IL-7 for 72 h.T
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in gene expression between T cells from WT mice and
mice overexpressing Stat5b but lacking lymphoma. Never-
theless, it is possible that transient cytokine-mediated acti-
vation at critical time points plays an important role in tu-
morigenesis in these animals. Interestingly, there was an
increased rate/incidence of lymphomas in Stat5b transgenic
mice expressing a TCR transgene, or after immunization.
This is potentially consistent with antigen/adjuvant-medi-
ated cytokine production (38), which in turn could, at least
transiently, activate the transgenic Stat5. However, sus-
tained Stat5 activation was not observed. Nevertheless, as
shown in Fig. 7 E in Stat5b/5C.C7 double transgenic
mice, a number of genes were induced over time. Addi-
tional work is needed to clarify the potential role of these
genes in oncogenesis. In addition to the Stat5 transgene
acting in a classical tyrosine phosphorylation-dependent
manner, alternative mechanisms are possible. For example,
Stat1 has been shown to affect expression of certain genes
by a mechanism independent of its tyrosine phosphoryla-
tion (39). Such a mechanism could potentially apply to
other STAT proteins as well.
Given that Stat5 can be activated in D10 cells (a T helper
cell clone) after TCR signaling (40), and that T cells from
Stat5a / Stat5b /  double knockout mice fail to prolifer-
ate in response to anti-CD3 stimulation (25, 41) and have
defective ERK activation (our unpublished observations),
we hypothesize that Stat5 transgenic mice might be more
susceptible to the effects of TCR-stimulation in vivo. As
CD8  T cell expansion and CD8  lymphomas are seen
even in mice expressing the class II–restricted 5C.C7 TCR
transgene, this indicates a particularly potent effect of the
Stat5 transgene in controlling CD8  T lineage develop-
Figure 7. Time-course analysis of Stat5b/5C.C7 and 5C.C7 mice. (A) CD8  thymocyte numbers increase over time in Stat5b/5C.C7 double trans-
genic mice. Each point represents a single mouse. (B) CD4/CD8 profile of Stat5b/5C.C7 and 5C.C7 transgenic mice over time. Representative profiles
are shown for the time points indicated (with total cellularity indicated above in parentheses). The 5C.C7 single transgenic mice either have significant
loss of thymocytes over time (panels c and d) or an expansion of CD4  cells with time (panels i and j), whereas the Stat5b/5C.C7 double transgenic mice
have an expansion of CD8  cells. (C) Anti-CD3 induced proliferation of total thymocytes. Each point represents a single mouse. (D) Shown is a den-
dogram resulting from unsupervised clustering of 6250 genes that were expressed “present” in any group. (E) Expression of genes that were found to be
more highly expressed in Stat5b transgenic mice with lymphoma (see Fig. 4 C and online supplemental material), were also analyzed over time in 5C.C7
and in Stat5b/5C.C7 mice. In A and C, the 12-wk-old group includes all mice 12–13 wk old.T
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ment. Moreover, the fact that the tumors arise earlier in
mice expressing a transgenic TCR or after immunization
indicates a role for TCR signaling and possibly selection in
the earlier development of these tumors.
In contrast to systems that have correlated constitutively
activated STAT proteins with oncogenesis, our Stat5a and
Stat5b transgenic models demonstrate that overexpression
of a WT (HA-tagged) STAT protein can also predispose to
malignant transformation. Because the transgenic vector we
used directs high level expression in lymphoid tissue, it is
not surprising that the tumors that developed in our mice
were lymphomas. However, given the ubiquitous expres-
sion of Stat5 proteins and the fact that they are activated by
many different cytokines and growth factors, we hypothe-
size that the oncogenic potential of Stat5a and Stat5b may
not be restricted to the immune system, and that overex-
pression in other tissues might cause other forms of neopla-
sia. Accordingly, Stat5a and Stat5b could prove to be ratio-
nal target molecules for manipulating the growth of a
number of different tumors. Finally, the fact that TCR/
antigen stimulation could augment the rate of lymphoma
formation in Stat5 transgenic mice has implications related
to tumor and vaccine immunology.
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